Ken Griffin Shattuck Labs, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 300 shares of STTK stock, worth $330. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 3,100
90.32%
Holding current value
$330
Previous $11,000
90.91%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding STTK
# of Institutions
80Shares Held
28.8MCall Options Held
300Put Options Held
1.2K-
Prosight Management, LP Dallas, TX5.68MShares$6.25 Million5.32% of portfolio
-
Redmile Group, LLC San Francisco, CA5.62MShares$6.18 Million1.28% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.9MShares$3.19 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$2.72 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.4MShares$2.64 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $46.6M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...